Abstract
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Keywords: COVID-19; Guillain-Barré syndrome; dysgeusia; sensory ataxia; vaccination.
【저자키워드】 COVID-19, vaccination., dysgeusia, Guillain-barrè syndrome, sensory ataxia, 【초록키워드】 Methylprednisolone, coronavirus disease, Coronavirus disease 2019, Intravenous immunoglobulin, COVID-19 vaccine, vaccination, therapy, Vaccines, Immunotherapy, variant, Symptom, Symptoms, dysgeusia, Immunoglobulin, autoantibodies, Pfizer-BioNTech, Guillain-barrè syndrome, sensory ataxia, autoantibody, Ataxia, second dose, syndrome, pulse, subtype, occurred, induce, ameliorated, ataxic, 【제목키워드】 mRNA, Guillain-barrè syndrome, Sensory,